The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller https://abelqphc359233.bloggip.com/40474841/high-roller-pharma-a-hazardous-bet